The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Mutant hematopoietic progenitor cells in MM associated with secondary primary malignancies
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses data from a longitudinal screening of patients with multiple myeloma (MM) for mutant hematopoietic progenitor cells (HPC) in the bone marrow and discusses their association with secondary primary malignancies (SPM). The mutational landscape of patients changed during their treatment, and those patients with mutant progenitor HPCs had a greater risk of developing an SPM, resulting in a subsequent decrease in overall survival. Dr Paiva hopes that this study will aid in developing a diagnostic laboratory test which will allow the patients at higher risk of SPM to be identified and will facilitate personalized treatment to reduce the risk of SPM. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Roche Glycart AG, Janssen, Sanofi, GSK, Takeda, Adaptive, Amgen, Bristol-Myers Squibb, Gilead, Oncopeptides
Research Funding: Roche Glycart AG, Sanofi, EngMab, GSK, Takeda, Bristol-Myers Squibb
Consultancy: Janssen, Sanofi, Bristol-Myers Squibb
